Pcn30 - Evidence Generation in a Early Access Strategy for Targeted Oncology Therapies: A Comparison in Non-Small Cell Lung Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.112
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prm70 - Non-Small Cell Lung Cancer Market Analysis for Targeted Therapies in Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Tabulated Summary of Targeted and Biologic Therapies for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

A Decade of Targeted Therapy for Non-Small Cell Lung Cancer

2017English

Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2013English

OA02 Targeted Next-Generation Sequencing Reveals Relapse-Associated Genomic Alterations in Early Stage Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Systematic Review of the Cost-Effectiveness of Targeted Therapies for Metastatic Non-Small Cell Lung Cancer (NSCLC)

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2014English

Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2017English

L-Blp25: A Peptide Vaccine Strategy in Non Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Inhibition of dUTPase Induces Synthetic Lethality With Thymidylate Synthase-Targeted Therapies in Non-Small Cell Lung Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy